Creative Medical Technology Holdings Inc (CELZ)

[gint1]

CELZ....NEWS!!!!

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7222/58039_c602caae64e47aa7_001full.jpg
Business Highlights
Debt
From January 1st, 2020 through May 31st, 2020 the company has reduced our debt by over $300,000 (22% reduction) and eliminated debt to one lender entirely. As sales continue to gain momentum, we are committed to reducing this debt further and to be cash flow positive by the end of 2020.
CaverStem® Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men
We started the New Year with the publication of our landmark results in the largest non-drug ED clinical trial in the Journal of Translational Medicine[1]. Healthcare Professional (HCP) Recruitment/Training saw a gain with 4 new practices coming onboard in the first 45 days with multiple other locations expressing interest.
The outbreak of COVID-19 affected our business as existing practices as well as interested practices were impacted by restrictions placed on physicians performing elective procedures and an uncertain economy.
In the past 4 weeks we have seen a resurgence in our business with reorders from existing practices as well as greater interest from new practices. Much of the interest is coming from referrals from existing practices successfully treating patients.
We expect this increase to continue and to grow in the 3rd quarter.
FemCelz® Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction
As described within our CaverStem® summary, FemCelz® was also impacted by COVID-19. We are continuing to expand our practice base and anticipate a positive incline in this business as well.
OvaStemTM Regenerative Stem Cell Procedure for Treatment of Premature Ovarian Failure
We are pleased to announce notification from the US Patent and Trademark Office that our Patent claims have been issued. The issued claims are broad and provide patent protection for the use of stem cells from multiple origins including autologous bone marrow derived stem cells and allogenic stem cells derived from sources such as amniotic fluid and cord blood.
The broad claims provide the company significant flexibility as we shall pursue the Autologous method of treatment as CaverStem® and FemCelz®. We may also pursue the Allogenic method which would require Clinical Trials and FDA approval. It is our goal to seek out a joint venture partner to execute on the Allogenic model as significant time and resources would be required.
AmnioStem™ and StemSpine®
Updates will be released soon.